{"id":999173,"date":"2026-08-31T15:10:29","date_gmt":"2026-08-31T19:10:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/"},"modified":"2026-08-31T15:10:29","modified_gmt":"2026-08-31T19:10:29","slug":"beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/","title":{"rendered":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines<\/b><\/p>\n<p class=\"bwalignc\"><i>Agreement advances patient access and strengthens BeOne&#8217;s long-term commitment to U.S. innovation and manufacturing<\/i><\/p>\n<p>SAN CARLOS, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.beonemedicines.com&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=BeOne+Medicines&amp;index=1&amp;md5=349420f9ebd4fe3801e5a843b45bfdd1\">BeOne Medicines<\/a>, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne&#8217;s longstanding commitment to patient access and investment in research and scientific innovation.<\/p>\n<p><b>John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said:<br \/>\n<br \/><\/b>\u201cAt BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration\u2019s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.\u201d<\/p>\n<p><b>Improved access to oncology medicines for patients<br \/>\n<br \/><\/b>This announcement reflects BeOne\u2019s participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model and the company\u2019s commitment to pricing future FDA-approved products in line with other key developed markets.<\/p>\n<p><b>Increased manufacturing and investment<br \/>\n<br \/><\/b>Through continued investments in U.S. manufacturing, BeOne is enhancing supply continuity and manufacturing flexibility while supporting patient access to innovative medicines.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nBeOne entered into an onshoring agreement with the U.S. government, securing an exemption from Section 232 pharmaceutical tariffs that recognizes the company\u2019s significant and ongoing investments in US. manufacturing.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nThe company <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.beonemedicines.com%2Fnews%2Fbeone-medicines-expands-us-manufacturing-with-total-investment-of-more-than-dollar1-billion-to-advance%2Fed73c96c-c5b5-4fbe-929a-d13e2f3f4a61&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=recently+announced&amp;index=2&amp;md5=2ca43e9545d32ee578ed99f3c92df7cc\">recently announced<\/a> a $300 million onshoring investment in its flagship clinical and commercial-stage manufacturing and research and development facility in Hopewell, NJ, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will add small-molecule manufacturing capacity, create approximately 120 full-time jobs and enhance BeOne\u2019s ability to manufacture medicines in the states and advance its oncology pipeline of more than 35 clinical- and commercial-stage assets.<\/p>\n<\/li>\n<\/ul>\n<p>\nThe U.S. is an important hub for BeOne&#8217;s scientific, clinical and manufacturing operations. BeOne employs more than 2,000 U.S. colleagues within a global team of more than 12,000 across six continents. In 2025, the company generated nearly $2 billion in direct U.S. economic impact and invested $1 billion in U.S. research and development. BeOne is also advancing one of oncology&#8217;s broadest pipelines through 93 clinical trials at approximately 1,100 sites across 45 states and one territory, supported by more than 650 investigators.<\/p>\n<p><b>About BeOne<br \/>\n<br \/><\/b>BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.beonemedicines.com&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=www.beonemedicines.com&amp;index=3&amp;md5=041581efed2aa93b6f956a8aa45b0b88\">www.beonemedicines.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbeonemedicines%2F&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=22434df3196235372dd0cf0167924790\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FBeOneMedicines&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=X&amp;index=5&amp;md5=6860d55a9af3dc4ce2089becb6508ca5\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FBeOneMeds&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=9b62865ddeac98f6117c13972a505d86\">Facebook<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fbeonemedicines%2F&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=db44691900898d5bcd4638b8304f36d5\">Instagram<\/a>.<\/p>\n<p><b>Forward-Looking Statement<br \/>\n<br \/><\/b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne helping more eligible patients in the U.S. access innovative cancer medicines while supporting continued investment in U.S. research, manufacturing and scientific innovation; BeOne reaching patients around the world faster, more reliably and at greater scale; BeOne pricing future FDA-approved products in line with other key developed markets; BeOne\u2019s commitment to continued investment in U.S. manufacturing, stronger supply chain resilience, and support of patient access to innovative medicines; and BeOne\u2019s plans, commitments, aspirations, and goals under the heading \u201cAbout BeOne.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne\u2019s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne\u2019s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne\u2019s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne\u2019s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeOne\u2019s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne\u2019s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.<\/p>\n<p>\nTo access BeOne media resources, please visit our<b \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2Fnewsroom%2F&amp;esheet=54596665&amp;newsitemid=20260831047788&amp;lan=en-US&amp;anchor=Newsroom&amp;index=8&amp;md5=5382948ebfb137b8e4421deefd2adc6b\"><b>Newsroom<\/b><\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260831047788\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260831047788\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Liza Heapes<br \/>\n<br \/>+1 857-302-5663<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@beonemed.com\">ir@beonemed.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Kyle Blankenship<br \/>\n<br \/>+ 1 667-351-5176<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@beonemed.com\">media@beonemed.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Other Manufacturing Medical Supplies FDA Public Policy\/Government Manufacturing Biotechnology White House\/Federal Government Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260831047788\/en\/2494825\/3\/BGI2404_BeOne_Primary_Logo_RGB_M04_V01.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines Agreement advances patient access and strengthens BeOne&#8217;s long-term commitment to U.S. innovation and manufacturing SAN CARLOS, Calif.&#8211;(BUSINESS WIRE)&#8211;BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne&#8217;s longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: \u201cAt BeOne, we believe every patient should benefit from innovative cancer therapies. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999173","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines Agreement advances patient access and strengthens BeOne&#8217;s long-term commitment to U.S. innovation and manufacturing SAN CARLOS, Calif.&#8211;(BUSINESS WIRE)&#8211;BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne&#8217;s longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: \u201cAt BeOne, we believe every patient should benefit from innovative cancer therapies. &hellip; Continue reading &quot;BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T19:10:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines\",\"datePublished\":\"2026-08-31T19:10:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/\"},\"wordCount\":926,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/\",\"name\":\"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-31T19:10:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Market Newsdesk","og_description":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines Agreement advances patient access and strengthens BeOne&#8217;s long-term commitment to U.S. innovation and manufacturing SAN CARLOS, Calif.&#8211;(BUSINESS WIRE)&#8211;BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne&#8217;s longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: \u201cAt BeOne, we believe every patient should benefit from innovative cancer therapies. &hellip; Continue reading \"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-31T19:10:29+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines","datePublished":"2026-08-31T19:10:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/"},"wordCount":926,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/","name":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-31T19:10:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260831047788r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beone-medicines-announces-voluntary-agreement-with-u-s-government-to-expand-access-to-innovative-cancer-medicines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999173"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999173\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}